Drug development for osteoarthritis (OA) has faced significant challenges, mainly due to the lack of alignment between joint structure observations and patient-reported outcomes (PROs), such as pain. Weight loss has been linked to positive effects on symptomatic outcomes. Blood-based biomarkers indicating collagen and extracellular matrix turnover can be used to measure injury severity in specific tissues, offering a more precise assessment of disease progression. This study aimed to explore the relationship between obesity and PROs and its impact on serum and urinary biomarkers of bone (CTX-I and osteocalcin), synovial (type III collagen degradation and C3M), and cartilage (type II collagen degradation, CTX-II, and C2M) turnover.

To investigate longitudinal IgG4 dynamics in IgG4-related disease (IgG4-RD), identify the predictive value of IgG4 rising kinetics for relapse and evaluate outcomes of intensified treatment following IgG4 surge.

To identify HLA associations with clinical and autoantibody-defined subgroups of idiopathic inflammatory myopathy (IIM) and predict potential immunogenic epitopes presented by subgroup-specific HLA alleles.

Anti-synthetase syndrome (ASyS) is a rare autoimmune disorder defined by anti-synthetase antibodies. While malignancy is established in DM, its association with ASyS remains unclear. We aimed to estimate malignancy prevalence in ASyS and assess whether autoantibody subtype, age, sex or clinical features influence malignancy risk.

Systemic sclerosis-associated heart involvement (SHI) is an enigmatic disease manifestation associated with high mortality. The Scleroderma Clinical Trials Consortium (SCTC) Cardiac Working Group developed SHI classification criteria to enable systematic investigation of this condition.

To assess the demographic and clinical characteristics (including the burden of comorbidities) and the survival rates of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) and to compare them with those of contemporary patients with idiopathic PAH (IPAH). We also evaluated the impact of emerging age-related comorbidities on survival.

Systemic sclerosis (SSc) is a connective tissue disease that can affect multiple organs, including the musculoskeletal system and the temporomandibular joint (TMJ). This study aimed to determine the frequency and clinical characteristics of temporomandibular disorders (TMD) among patients with SSc.

The optimal treatment of polymyalgia rheumatica (PMR) is far from being fully elucidated. Only a few trials explored the role of conventional DMARDs: none of them adequately ruled out subclinical giant cell arteritis (GCA). The aim of this study was to assess whether the precocious administration of methotrexate (MTX) and a short course of glucocorticoids (GCs) could be safe and effective in recently diagnosed PMR.

Rheumatic disease registries systematically collect real-world longitudinal data, improving patient care and research. Despite the high burden of rheumatic diseases, national registries are scarce in the Middle East. Rheumatology Research Center, with support from Iran’s Ministry of Health, launched Rheumatry in 2016 as the country’s first national rheumatic disease registry.

Inborn errors of metabolism comprise a clinically diverse group of conditions that arise from the decreased activity of an enzyme or metabolite transporter and subsequent blockade in a metabolic pathway. These disorders are typically considered in the differential diagnosis of critically ill neonates or young children presenting with hypoglycaemia, metabolic acidosis or hyperammonaemia. However, beyond these classic presentations, a broader group of inborn errors of metabolism can manifest more subtly, with progressive articular and multi-systemic involvement that mimics or overlaps with typical features of rheumatological disease. Consequently, these conditions might be misdiagnosed for years as rheumatological diseases, including juvenile idiopathic arthritis, systemic sclerosis, idiopathic inflammatory myopathies and systemic lupus erythematosus. Moreover, these disorders provide unique opportunities to understand the complex interplay between metabolism and immune function. With the growing availability of disease-modifying therapies for inborn errors of metabolism, rheumatologists must be able to recognize these disorders, particularly in patients with atypical features or treatment-refractory disease.

WNT5A is a noncanonical WNT ligand that is overexpressed in autoimmune systemic sclerosis (SSc). While the pathogenic effects of WNT5A have been established in SSc fibroblasts, its contribution to profibrotic SSc macrophage activation is unknown. The goal of this study was to determine the effects of WNT5A on fibrotic macrophage activation.

In SLE, expanded B cell subtypes like double-negative 2 (DN2) may harbour autoreactivity, which may be linked to impaired checkpoint regulation. We investigated checkpoint molecule CD72 on B cells, its clinical associations, and dynamic changes upon rituximab (RTX) treatment.

Assessing quality of life in patients with axial spondyloarthritis (axSpA) is essential for capturing the full burden of the disease beyond clinical and imaging findings. Quality of life measures support clinicians in identifying unmet patient needs and informing treatment decisions. The aim of this study was to develop and validate the first Bulgarian version of the Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire.

Lupus nephritis (LN) is a major cause of morbidity in childhood-onset systemic lupus erythematosus (cSLE). Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are recommended first-line induction therapies, yet comparative pediatric real-world data, particularly from Asian populations, remain limited. This study compared the effectiveness of CYC and MMF for induction of renal remission and evaluated patterns and predictors of treatment switching among Filipino children with LN.

Mycophenolate mofetil (MMF) is routinely used in early diffuse cutaneous systemic sclerosis (dcSSc) but not in limited cutaneous (lc)SSc. This may miss an opportunity to slow disease progression. MINIMISE-Pilot tested the feasibility of an open-label event-driven randomised trial of MMF vs no immunosuppression in lcSSc.

Neurological involvement in Sjögren's disease (neuro-SjD), reported by up to 20% of patients, represents a highly relevant extra-glandular manifestation. Owing to the clinical complexity, frequent diagnostic delay and the poor response to treatment, neuro-SjD remains a major unmet need. This study aimed to better understand the burden of neuro-SjD from the patient perspective, focusing on the overall care journey.